$225.74
-0.24[-0.11%]
At close: Jun 11
$225.74
0[0.00%]
After Hours: 4:07PM EDT
Biogen Stock (NASDAQ:BIIB), Analyst Ratings, Price Targets, Predictions
Biogen Inc has a consensus price target of $291.84, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, RBC Capital, and HC Wainwright & Co. on June 5, 2024, May 29, 2024, and May 23, 2024. With an average price target of $311.33 between RBC Capital, RBC Capital, and HC Wainwright & Co., there's an implied 37.92% upside for Biogen Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
Needham
Truist Securities
HSBC
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Biogen
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/05/2024 | Buy Now | 40.43% | RBC Capital | Brian Abrahams | $317 → $317 | Reiterates | Outperform → Outperform | Get Alert |
| 05/29/2024 | Buy Now | 40.43% | RBC Capital | Brian Abrahams | → $317 | Reiterates | Outperform → Outperform | Get Alert |
| 05/23/2024 | Buy Now | 32.9% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | 30.24% | Needham | Ami Fadia | → $294 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 50.62% | Truist Securities | Robyn Karnauskas | $340 → $340 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 51.5% | HSBC | Morten Herholdt | $339 → $342 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 19.61% | Oppenheimer | Jay Olson | $270 → $270 | Maintains | Outperform | Get Alert |
| 04/25/2024 | Buy Now | -11.4% | Barclays | Carter Gould | $215 → $200 | Maintains | Equal-Weight | Get Alert |
| 04/25/2024 | Buy Now | -4.76% | Wedbush | Laura Chico | $213 → $215 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 32.9% | HC Wainwright & Co. | Andrew Fein | $325 → $300 | Maintains | Buy | Get Alert |
| 04/25/2024 | Buy Now | 30.24% | Needham | Ami Fadia | → $294 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2024 | Buy Now | 30.24% | Needham | Ami Fadia | → $294 | Reiterates | Buy → Buy | Get Alert |
| 04/19/2024 | Buy Now | 19.61% | Oppenheimer | Jay Olson | $290 → $270 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | -5.2% | UBS | Colin Bristow | $250 → $214 | Maintains | Neutral | Get Alert |
| 04/17/2024 | Buy Now | -5.64% | Wedbush | Laura Chico | $245 → $213 | Maintains | Neutral | Get Alert |
| 04/12/2024 | Buy Now | 15.18% | B of A Securities | Geoff Meacham | $280 → $260 | Maintains | Neutral | Get Alert |
| 04/11/2024 | Buy Now | 6.32% | JP Morgan | Chris Schott | $270 → $240 | Maintains | Neutral | Get Alert |
| 04/04/2024 | Buy Now | -4.76% | Barclays | Carter Gould | $230 → $215 | Maintains | Equal-Weight | Get Alert |
| 03/25/2024 | Buy Now | 50.62% | Truist Securities | Robyn Karnauskas | → $340 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 61.25% | RBC Capital | Brian Abrahams | → $364 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 22.71% | Mizuho | Salim Syed | $355 → $277 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 37.77% | Cantor Fitzgerald | Eric Schmidt | → $311 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2024 | Buy Now | 35.11% | Canaccord Genuity | Sumant Kulkarni | $310 → $305 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 10.75% | UBS | Colin Bristow | $276 → $250 | Maintains | Neutral | Get Alert |
| 02/14/2024 | Buy Now | 39.98% | Baird | Brian Skorney | $333 → $316 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 43.97% | Piper Sandler | Christopher Raymond | $350 → $325 | Maintains | Overweight | Get Alert |
| 02/14/2024 | Buy Now | 26.25% | BMO Capital | Evan Seigerman | $295 → $285 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 28.47% | Oppenheimer | Jay Olson | $295 → $290 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 61.25% | RBC Capital | Brian Abrahams | $379 → $364 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 6.32% | Wells Fargo | Mohit Bansal | $315 → $240 | Downgrade | Overweight → Equal-Weight | Get Alert |
FAQ
What is the target price for Biogen (BIIB)?
The latest price target for Biogen (NASDAQ: BIIB) was reported by RBC Capital on June 5, 2024. The analyst firm set a price target for $317.00 expecting BIIB to rise to within 12 months (a possible 40.43% upside). 75 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biogen (BIIB)?
The latest analyst rating for Biogen (NASDAQ: BIIB) was provided by RBC Capital, and Biogen reiterated their outperform rating.
When was the last upgrade for Biogen (BIIB)?
The last upgrade for Biogen Inc happened on December 7, 2023 when Raymond James raised their price target to $283. Raymond James previously had a market perform for Biogen Inc.
When was the last downgrade for Biogen (BIIB)?
The last downgrade for Biogen Inc happened on February 14, 2024 when Wells Fargo changed their price target from $315 to $240 for Biogen Inc.
When is the next analyst rating going to be posted or updated for Biogen (BIIB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on June 5, 2024 so you should expect the next rating to be made available sometime around June 5, 2025.
Is the Analyst Rating Biogen (BIIB) correct?
While ratings are subjective and will change, the latest Biogen (BIIB) rating was a reiterated with a price target of $317.00 to $317.00. The current price Biogen (BIIB) is trading at is $225.74, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.